nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—kidney cancer	0.68	1	CbGaD
Pseudoephedrine—CYP2D6—Temsirolimus—kidney cancer	0.0201	0.372	CbGbCtD
Pseudoephedrine—CYP2D6—Pazopanib—kidney cancer	0.0105	0.195	CbGbCtD
Pseudoephedrine—CYP2D6—Erlotinib—kidney cancer	0.00752	0.139	CbGbCtD
Pseudoephedrine—CYP2D6—Sorafenib—kidney cancer	0.00612	0.113	CbGbCtD
Pseudoephedrine—CYP2D6—Vinblastine—kidney cancer	0.00604	0.112	CbGbCtD
Pseudoephedrine—CYP2D6—Doxorubicin—kidney cancer	0.00371	0.0687	CbGbCtD
Pseudoephedrine—Etomidate—SLC2A1—kidney cancer	0.00288	0.664	CrCbGaD
Pseudoephedrine—Ephedrine—ACHE—kidney cancer	0.000696	0.161	CrCbGaD
Pseudoephedrine—IL2—renal system—kidney cancer	0.000673	0.215	CbGeAlD
Pseudoephedrine—IL2—kidney—kidney cancer	0.000651	0.207	CbGeAlD
Pseudoephedrine—Dyspnoea—Temsirolimus—kidney cancer	0.00046	0.00506	CcSEcCtD
Pseudoephedrine—Bradycardia—Sunitinib—kidney cancer	0.00046	0.00505	CcSEcCtD
Pseudoephedrine—Muscle spasms—Everolimus—kidney cancer	0.000452	0.00497	CcSEcCtD
Pseudoephedrine—Decreased appetite—Temsirolimus—kidney cancer	0.000449	0.00493	CcSEcCtD
Pseudoephedrine—Dysuria—Vincristine—kidney cancer	0.000446	0.0049	CcSEcCtD
Pseudoephedrine—Pain—Temsirolimus—kidney cancer	0.000442	0.00485	CcSEcCtD
Pseudoephedrine—Tremor—Everolimus—kidney cancer	0.000441	0.00484	CcSEcCtD
Pseudoephedrine—Insomnia—Pazopanib—kidney cancer	0.00044	0.00483	CcSEcCtD
Pseudoephedrine—Dyspnoea—Pazopanib—kidney cancer	0.000434	0.00476	CcSEcCtD
Pseudoephedrine—Agitation—Everolimus—kidney cancer	0.000432	0.00475	CcSEcCtD
Pseudoephedrine—Dyspepsia—Pazopanib—kidney cancer	0.000428	0.0047	CcSEcCtD
Pseudoephedrine—Vertigo—Vinblastine—kidney cancer	0.000424	0.00466	CcSEcCtD
Pseudoephedrine—Decreased appetite—Pazopanib—kidney cancer	0.000423	0.00464	CcSEcCtD
Pseudoephedrine—Arrhythmia—Sorafenib—kidney cancer	0.000419	0.0046	CcSEcCtD
Pseudoephedrine—Pain—Pazopanib—kidney cancer	0.000416	0.00457	CcSEcCtD
Pseudoephedrine—Palpitations—Everolimus—kidney cancer	0.000416	0.00457	CcSEcCtD
Pseudoephedrine—Ephedrine—BCHE—kidney cancer	0.000409	0.0945	CrCbGaD
Pseudoephedrine—Body temperature increased—Temsirolimus—kidney cancer	0.000408	0.00448	CcSEcCtD
Pseudoephedrine—Hypertension—Vinblastine—kidney cancer	0.000408	0.00448	CcSEcCtD
Pseudoephedrine—Sweating—Vincristine—kidney cancer	0.000408	0.00448	CcSEcCtD
Pseudoephedrine—Hypertension—Everolimus—kidney cancer	0.000406	0.00446	CcSEcCtD
Pseudoephedrine—Arrhythmia—Sunitinib—kidney cancer	0.000403	0.00443	CcSEcCtD
Pseudoephedrine—Chest pain—Everolimus—kidney cancer	0.000401	0.0044	CcSEcCtD
Pseudoephedrine—Anxiety—Everolimus—kidney cancer	0.000399	0.00439	CcSEcCtD
Pseudoephedrine—Muscle spasms—Sorafenib—kidney cancer	0.000393	0.00431	CcSEcCtD
Pseudoephedrine—Sweating—Gemcitabine—kidney cancer	0.000387	0.00425	CcSEcCtD
Pseudoephedrine—Chest pain—Erlotinib—kidney cancer	0.000387	0.00425	CcSEcCtD
Pseudoephedrine—Anxiety—Erlotinib—kidney cancer	0.000385	0.00423	CcSEcCtD
Pseudoephedrine—Hallucination—Vincristine—kidney cancer	0.00038	0.00417	CcSEcCtD
Pseudoephedrine—Muscle spasms—Sunitinib—kidney cancer	0.000378	0.00415	CcSEcCtD
Pseudoephedrine—Tachycardia—Everolimus—kidney cancer	0.000375	0.00412	CcSEcCtD
Pseudoephedrine—Delirium—Doxorubicin—kidney cancer	0.000371	0.00408	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Everolimus—kidney cancer	0.000371	0.00408	CcSEcCtD
Pseudoephedrine—Asthenia—Temsirolimus—kidney cancer	0.00037	0.00407	CcSEcCtD
Pseudoephedrine—Anorexia—Vinblastine—kidney cancer	0.000367	0.00404	CcSEcCtD
Pseudoephedrine—Anorexia—Everolimus—kidney cancer	0.000366	0.00402	CcSEcCtD
Pseudoephedrine—Dysuria—Paclitaxel—kidney cancer	0.000354	0.00389	CcSEcCtD
Pseudoephedrine—Anorexia—Erlotinib—kidney cancer	0.000353	0.00388	CcSEcCtD
Pseudoephedrine—Hypertension—Sorafenib—kidney cancer	0.000353	0.00387	CcSEcCtD
Pseudoephedrine—Asthenia—Pazopanib—kidney cancer	0.000349	0.00383	CcSEcCtD
Pseudoephedrine—Insomnia—Everolimus—kidney cancer	0.000347	0.00382	CcSEcCtD
Pseudoephedrine—Irritability—Capecitabine—kidney cancer	0.000343	0.00377	CcSEcCtD
Pseudoephedrine—Dyspnoea—Everolimus—kidney cancer	0.000342	0.00376	CcSEcCtD
Pseudoephedrine—Urinary retention—Capecitabine—kidney cancer	0.000342	0.00376	CcSEcCtD
Pseudoephedrine—Dizziness—Temsirolimus—kidney cancer	0.000341	0.00375	CcSEcCtD
Pseudoephedrine—Hypertension—Sunitinib—kidney cancer	0.000339	0.00373	CcSEcCtD
Pseudoephedrine—Dyspepsia—Everolimus—kidney cancer	0.000338	0.00371	CcSEcCtD
Pseudoephedrine—Insomnia—Erlotinib—kidney cancer	0.000335	0.00368	CcSEcCtD
Pseudoephedrine—Decreased appetite—Vinblastine—kidney cancer	0.000335	0.00368	CcSEcCtD
Pseudoephedrine—Chest pain—Sunitinib—kidney cancer	0.000335	0.00368	CcSEcCtD
Pseudoephedrine—Decreased appetite—Everolimus—kidney cancer	0.000334	0.00367	CcSEcCtD
Pseudoephedrine—Dyspnoea—Erlotinib—kidney cancer	0.00033	0.00363	CcSEcCtD
Pseudoephedrine—Pain—Vinblastine—kidney cancer	0.00033	0.00362	CcSEcCtD
Pseudoephedrine—Pain—Everolimus—kidney cancer	0.000328	0.00361	CcSEcCtD
Pseudoephedrine—Vomiting—Temsirolimus—kidney cancer	0.000328	0.00361	CcSEcCtD
Pseudoephedrine—Dyspepsia—Erlotinib—kidney cancer	0.000326	0.00358	CcSEcCtD
Pseudoephedrine—Rash—Temsirolimus—kidney cancer	0.000326	0.00358	CcSEcCtD
Pseudoephedrine—Dermatitis—Temsirolimus—kidney cancer	0.000325	0.00357	CcSEcCtD
Pseudoephedrine—Arrhythmia—Gemcitabine—kidney cancer	0.000324	0.00356	CcSEcCtD
Pseudoephedrine—Headache—Temsirolimus—kidney cancer	0.000323	0.00355	CcSEcCtD
Pseudoephedrine—Decreased appetite—Erlotinib—kidney cancer	0.000322	0.00354	CcSEcCtD
Pseudoephedrine—Dizziness—Pazopanib—kidney cancer	0.000322	0.00353	CcSEcCtD
Pseudoephedrine—CYP2D6—urine—kidney cancer	0.000321	0.102	CbGeAlD
Pseudoephedrine—Anorexia—Sorafenib—kidney cancer	0.000318	0.00349	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Vinblastine—kidney cancer	0.000318	0.00349	CcSEcCtD
Pseudoephedrine—Pain—Erlotinib—kidney cancer	0.000317	0.00348	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Everolimus—kidney cancer	0.000316	0.00348	CcSEcCtD
Pseudoephedrine—Vomiting—Pazopanib—kidney cancer	0.000309	0.0034	CcSEcCtD
Pseudoephedrine—Bradycardia—Paclitaxel—kidney cancer	0.000309	0.00339	CcSEcCtD
Pseudoephedrine—Rash—Pazopanib—kidney cancer	0.000307	0.00337	CcSEcCtD
Pseudoephedrine—Nausea—Temsirolimus—kidney cancer	0.000307	0.00337	CcSEcCtD
Pseudoephedrine—Dermatitis—Pazopanib—kidney cancer	0.000306	0.00337	CcSEcCtD
Pseudoephedrine—Anorexia—Sunitinib—kidney cancer	0.000306	0.00336	CcSEcCtD
Pseudoephedrine—Agitation—Vincristine—kidney cancer	0.000306	0.00336	CcSEcCtD
Pseudoephedrine—Headache—Pazopanib—kidney cancer	0.000305	0.00335	CcSEcCtD
Pseudoephedrine—Body temperature increased—Everolimus—kidney cancer	0.000304	0.00333	CcSEcCtD
Pseudoephedrine—Angina pectoris—Capecitabine—kidney cancer	0.000303	0.00333	CcSEcCtD
Pseudoephedrine—Vertigo—Vincristine—kidney cancer	0.000299	0.00328	CcSEcCtD
Pseudoephedrine—Dyspnoea—Sorafenib—kidney cancer	0.000297	0.00326	CcSEcCtD
Pseudoephedrine—Dyspepsia—Sorafenib—kidney cancer	0.000293	0.00322	CcSEcCtD
Pseudoephedrine—Body temperature increased—Erlotinib—kidney cancer	0.000293	0.00322	CcSEcCtD
Pseudoephedrine—Dysuria—Capecitabine—kidney cancer	0.000291	0.00319	CcSEcCtD
Pseudoephedrine—Insomnia—Sunitinib—kidney cancer	0.00029	0.00319	CcSEcCtD
Pseudoephedrine—Decreased appetite—Sorafenib—kidney cancer	0.00029	0.00318	CcSEcCtD
Pseudoephedrine—Anorexia—Dactinomycin—kidney cancer	0.000289	0.00318	CcSEcCtD
Pseudoephedrine—Nausea—Pazopanib—kidney cancer	0.000289	0.00317	CcSEcCtD
Pseudoephedrine—Hypertension—Vincristine—kidney cancer	0.000287	0.00315	CcSEcCtD
Pseudoephedrine—Dyspnoea—Sunitinib—kidney cancer	0.000286	0.00314	CcSEcCtD
Pseudoephedrine—Pain—Sorafenib—kidney cancer	0.000285	0.00313	CcSEcCtD
Pseudoephedrine—Dyspepsia—Sunitinib—kidney cancer	0.000282	0.0031	CcSEcCtD
Pseudoephedrine—Decreased appetite—Sunitinib—kidney cancer	0.000279	0.00306	CcSEcCtD
Pseudoephedrine—Asthenia—Vinblastine—kidney cancer	0.000277	0.00304	CcSEcCtD
Pseudoephedrine—Asthenia—Everolimus—kidney cancer	0.000276	0.00303	CcSEcCtD
Pseudoephedrine—Pain—Sunitinib—kidney cancer	0.000274	0.00301	CcSEcCtD
Pseudoephedrine—Hypertension—Gemcitabine—kidney cancer	0.000272	0.00299	CcSEcCtD
Pseudoephedrine—Arrhythmia—Paclitaxel—kidney cancer	0.000271	0.00298	CcSEcCtD
Pseudoephedrine—Chest pain—Gemcitabine—kidney cancer	0.000269	0.00295	CcSEcCtD
Pseudoephedrine—Asthenia—Erlotinib—kidney cancer	0.000266	0.00292	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dactinomycin—kidney cancer	0.000264	0.0029	CcSEcCtD
Pseudoephedrine—Body temperature increased—Sorafenib—kidney cancer	0.000264	0.00289	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Vincristine—kidney cancer	0.000262	0.00288	CcSEcCtD
Pseudoephedrine—Pain—Dactinomycin—kidney cancer	0.00026	0.00285	CcSEcCtD
Pseudoephedrine—Tension—Paclitaxel—kidney cancer	0.000259	0.00285	CcSEcCtD
Pseudoephedrine—Anorexia—Vincristine—kidney cancer	0.000259	0.00284	CcSEcCtD
Pseudoephedrine—Nervousness—Paclitaxel—kidney cancer	0.000256	0.00282	CcSEcCtD
Pseudoephedrine—Dizziness—Vinblastine—kidney cancer	0.000255	0.0028	CcSEcCtD
Pseudoephedrine—Dizziness—Everolimus—kidney cancer	0.000254	0.00279	CcSEcCtD
Pseudoephedrine—Muscle spasms—Paclitaxel—kidney cancer	0.000254	0.00279	CcSEcCtD
Pseudoephedrine—Body temperature increased—Sunitinib—kidney cancer	0.000254	0.00279	CcSEcCtD
Pseudoephedrine—Bradycardia—Capecitabine—kidney cancer	0.000253	0.00278	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dactinomycin—kidney cancer	0.00025	0.00275	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000249	0.00273	CcSEcCtD
Pseudoephedrine—Tremor—Paclitaxel—kidney cancer	0.000247	0.00272	CcSEcCtD
Pseudoephedrine—Insomnia—Vincristine—kidney cancer	0.000245	0.0027	CcSEcCtD
Pseudoephedrine—Anorexia—Gemcitabine—kidney cancer	0.000245	0.0027	CcSEcCtD
Pseudoephedrine—Vomiting—Vinblastine—kidney cancer	0.000245	0.00269	CcSEcCtD
Pseudoephedrine—Dizziness—Erlotinib—kidney cancer	0.000245	0.00269	CcSEcCtD
Pseudoephedrine—Vomiting—Everolimus—kidney cancer	0.000244	0.00268	CcSEcCtD
Pseudoephedrine—Agitation—Paclitaxel—kidney cancer	0.000243	0.00267	CcSEcCtD
Pseudoephedrine—Rash—Everolimus—kidney cancer	0.000242	0.00266	CcSEcCtD
Pseudoephedrine—Dermatitis—Everolimus—kidney cancer	0.000242	0.00266	CcSEcCtD
Pseudoephedrine—Headache—Vinblastine—kidney cancer	0.000242	0.00265	CcSEcCtD
Pseudoephedrine—Headache—Everolimus—kidney cancer	0.000241	0.00264	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dactinomycin—kidney cancer	0.00024	0.00264	CcSEcCtD
Pseudoephedrine—Asthenia—Sorafenib—kidney cancer	0.000239	0.00263	CcSEcCtD
Pseudoephedrine—Vertigo—Paclitaxel—kidney cancer	0.000237	0.00261	CcSEcCtD
Pseudoephedrine—Decreased appetite—Vincristine—kidney cancer	0.000236	0.00259	CcSEcCtD
Pseudoephedrine—Vomiting—Erlotinib—kidney cancer	0.000236	0.00259	CcSEcCtD
Pseudoephedrine—Rash—Erlotinib—kidney cancer	0.000234	0.00257	CcSEcCtD
Pseudoephedrine—Dermatitis—Erlotinib—kidney cancer	0.000233	0.00256	CcSEcCtD
Pseudoephedrine—Palpitations—Paclitaxel—kidney cancer	0.000233	0.00256	CcSEcCtD
Pseudoephedrine—Insomnia—Gemcitabine—kidney cancer	0.000233	0.00256	CcSEcCtD
Pseudoephedrine—Benzyl alcohol—CYP1A1—kidney cancer	0.000233	0.0537	CrCbGaD
Pseudoephedrine—Headache—Erlotinib—kidney cancer	0.000232	0.00255	CcSEcCtD
Pseudoephedrine—Pain—Vincristine—kidney cancer	0.000232	0.00255	CcSEcCtD
Pseudoephedrine—Asthenia—Sunitinib—kidney cancer	0.00023	0.00253	CcSEcCtD
Pseudoephedrine—Dyspnoea—Gemcitabine—kidney cancer	0.000229	0.00252	CcSEcCtD
Pseudoephedrine—Nausea—Vinblastine—kidney cancer	0.000229	0.00252	CcSEcCtD
Pseudoephedrine—Nausea—Everolimus—kidney cancer	0.000228	0.00251	CcSEcCtD
Pseudoephedrine—Hypertension—Paclitaxel—kidney cancer	0.000228	0.0025	CcSEcCtD
Pseudoephedrine—Chest pain—Paclitaxel—kidney cancer	0.000225	0.00247	CcSEcCtD
Pseudoephedrine—Anxiety—Paclitaxel—kidney cancer	0.000224	0.00246	CcSEcCtD
Pseudoephedrine—Decreased appetite—Gemcitabine—kidney cancer	0.000224	0.00246	CcSEcCtD
Pseudoephedrine—Arrhythmia—Capecitabine—kidney cancer	0.000222	0.00244	CcSEcCtD
Pseudoephedrine—Dizziness—Sorafenib—kidney cancer	0.00022	0.00242	CcSEcCtD
Pseudoephedrine—Pain—Gemcitabine—kidney cancer	0.00022	0.00242	CcSEcCtD
Pseudoephedrine—Nausea—Erlotinib—kidney cancer	0.00022	0.00242	CcSEcCtD
Pseudoephedrine—Asthenia—Dactinomycin—kidney cancer	0.000218	0.00239	CcSEcCtD
Pseudoephedrine—Confusional state—Paclitaxel—kidney cancer	0.000217	0.00239	CcSEcCtD
Pseudoephedrine—Body temperature increased—Vincristine—kidney cancer	0.000214	0.00236	CcSEcCtD
Pseudoephedrine—Dizziness—Sunitinib—kidney cancer	0.000212	0.00233	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Gemcitabine—kidney cancer	0.000212	0.00233	CcSEcCtD
Pseudoephedrine—Vomiting—Sorafenib—kidney cancer	0.000212	0.00233	CcSEcCtD
Pseudoephedrine—Tachycardia—Paclitaxel—kidney cancer	0.00021	0.00231	CcSEcCtD
Pseudoephedrine—Rash—Sorafenib—kidney cancer	0.00021	0.00231	CcSEcCtD
Pseudoephedrine—Dermatitis—Sorafenib—kidney cancer	0.00021	0.00231	CcSEcCtD
Pseudoephedrine—Headache—Sorafenib—kidney cancer	0.000209	0.00229	CcSEcCtD
Pseudoephedrine—Muscle spasms—Capecitabine—kidney cancer	0.000208	0.00229	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000208	0.00229	CcSEcCtD
Pseudoephedrine—Anorexia—Paclitaxel—kidney cancer	0.000205	0.00226	CcSEcCtD
Pseudoephedrine—Vomiting—Sunitinib—kidney cancer	0.000204	0.00224	CcSEcCtD
Pseudoephedrine—Body temperature increased—Gemcitabine—kidney cancer	0.000203	0.00224	CcSEcCtD
Pseudoephedrine—Tremor—Capecitabine—kidney cancer	0.000203	0.00223	CcSEcCtD
Pseudoephedrine—Rash—Sunitinib—kidney cancer	0.000202	0.00222	CcSEcCtD
Pseudoephedrine—Dermatitis—Sunitinib—kidney cancer	0.000202	0.00222	CcSEcCtD
Pseudoephedrine—Headache—Sunitinib—kidney cancer	0.000201	0.00221	CcSEcCtD
Pseudoephedrine—Nausea—Sorafenib—kidney cancer	0.000198	0.00218	CcSEcCtD
Pseudoephedrine—Angina pectoris—Doxorubicin—kidney cancer	0.000195	0.00214	CcSEcCtD
Pseudoephedrine—Insomnia—Paclitaxel—kidney cancer	0.000195	0.00214	CcSEcCtD
Pseudoephedrine—Vertigo—Capecitabine—kidney cancer	0.000195	0.00214	CcSEcCtD
Pseudoephedrine—Asthenia—Vincristine—kidney cancer	0.000195	0.00214	CcSEcCtD
Pseudoephedrine—Vomiting—Dactinomycin—kidney cancer	0.000193	0.00212	CcSEcCtD
Pseudoephedrine—Dyspnoea—Paclitaxel—kidney cancer	0.000192	0.00211	CcSEcCtD
Pseudoephedrine—Palpitations—Capecitabine—kidney cancer	0.000191	0.0021	CcSEcCtD
Pseudoephedrine—Rash—Dactinomycin—kidney cancer	0.000191	0.0021	CcSEcCtD
Pseudoephedrine—Nausea—Sunitinib—kidney cancer	0.000191	0.00209	CcSEcCtD
Pseudoephedrine—Dyspepsia—Paclitaxel—kidney cancer	0.00019	0.00208	CcSEcCtD
Pseudoephedrine—Dysuria—Doxorubicin—kidney cancer	0.000187	0.00206	CcSEcCtD
Pseudoephedrine—Decreased appetite—Paclitaxel—kidney cancer	0.000187	0.00206	CcSEcCtD
Pseudoephedrine—Hypertension—Capecitabine—kidney cancer	0.000187	0.00205	CcSEcCtD
Pseudoephedrine—Asthenia—Gemcitabine—kidney cancer	0.000185	0.00203	CcSEcCtD
Pseudoephedrine—Chest pain—Capecitabine—kidney cancer	0.000184	0.00203	CcSEcCtD
Pseudoephedrine—Pain—Paclitaxel—kidney cancer	0.000184	0.00202	CcSEcCtD
Pseudoephedrine—Anxiety—Capecitabine—kidney cancer	0.000184	0.00202	CcSEcCtD
Pseudoephedrine—Nausea—Dactinomycin—kidney cancer	0.00018	0.00198	CcSEcCtD
Pseudoephedrine—Dizziness—Vincristine—kidney cancer	0.000179	0.00197	CcSEcCtD
Pseudoephedrine—Confusional state—Capecitabine—kidney cancer	0.000178	0.00196	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Paclitaxel—kidney cancer	0.000178	0.00195	CcSEcCtD
Pseudoephedrine—Tachycardia—Capecitabine—kidney cancer	0.000173	0.0019	CcSEcCtD
Pseudoephedrine—Vomiting—Vincristine—kidney cancer	0.000173	0.00189	CcSEcCtD
Pseudoephedrine—Sweating—Doxorubicin—kidney cancer	0.000171	0.00188	CcSEcCtD
Pseudoephedrine—Rash—Vincristine—kidney cancer	0.000171	0.00188	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Capecitabine—kidney cancer	0.000171	0.00188	CcSEcCtD
Pseudoephedrine—Dermatitis—Vincristine—kidney cancer	0.000171	0.00188	CcSEcCtD
Pseudoephedrine—Body temperature increased—Paclitaxel—kidney cancer	0.00017	0.00187	CcSEcCtD
Pseudoephedrine—Headache—Vincristine—kidney cancer	0.00017	0.00187	CcSEcCtD
Pseudoephedrine—Anorexia—Capecitabine—kidney cancer	0.000169	0.00185	CcSEcCtD
Pseudoephedrine—Vomiting—Gemcitabine—kidney cancer	0.000164	0.0018	CcSEcCtD
Pseudoephedrine—Bradycardia—Doxorubicin—kidney cancer	0.000163	0.00179	CcSEcCtD
Pseudoephedrine—Rash—Gemcitabine—kidney cancer	0.000162	0.00178	CcSEcCtD
Pseudoephedrine—Dermatitis—Gemcitabine—kidney cancer	0.000162	0.00178	CcSEcCtD
Pseudoephedrine—Headache—Gemcitabine—kidney cancer	0.000161	0.00177	CcSEcCtD
Pseudoephedrine—Nausea—Vincristine—kidney cancer	0.000161	0.00177	CcSEcCtD
Pseudoephedrine—Insomnia—Capecitabine—kidney cancer	0.00016	0.00176	CcSEcCtD
Pseudoephedrine—Dyspnoea—Capecitabine—kidney cancer	0.000158	0.00173	CcSEcCtD
Pseudoephedrine—Dyspepsia—Capecitabine—kidney cancer	0.000156	0.00171	CcSEcCtD
Pseudoephedrine—Asthenia—Paclitaxel—kidney cancer	0.000155	0.0017	CcSEcCtD
Pseudoephedrine—Decreased appetite—Capecitabine—kidney cancer	0.000154	0.00169	CcSEcCtD
Pseudoephedrine—Nausea—Gemcitabine—kidney cancer	0.000153	0.00168	CcSEcCtD
Pseudoephedrine—Pain—Capecitabine—kidney cancer	0.000151	0.00166	CcSEcCtD
Pseudoephedrine—ADRB1—cardiac atrium—kidney cancer	0.000151	0.0482	CbGeAlD
Pseudoephedrine—Feeling abnormal—Capecitabine—kidney cancer	0.000146	0.0016	CcSEcCtD
Pseudoephedrine—MAOA—nephron tubule—kidney cancer	0.000145	0.0464	CbGeAlD
Pseudoephedrine—Arrhythmia—Doxorubicin—kidney cancer	0.000143	0.00157	CcSEcCtD
Pseudoephedrine—Dizziness—Paclitaxel—kidney cancer	0.000143	0.00157	CcSEcCtD
Pseudoephedrine—Body temperature increased—Capecitabine—kidney cancer	0.00014	0.00154	CcSEcCtD
Pseudoephedrine—Tension—Doxorubicin—kidney cancer	0.000137	0.00151	CcSEcCtD
Pseudoephedrine—Vomiting—Paclitaxel—kidney cancer	0.000137	0.00151	CcSEcCtD
Pseudoephedrine—Rash—Paclitaxel—kidney cancer	0.000136	0.00149	CcSEcCtD
Pseudoephedrine—Dermatitis—Paclitaxel—kidney cancer	0.000136	0.00149	CcSEcCtD
Pseudoephedrine—Nervousness—Doxorubicin—kidney cancer	0.000136	0.00149	CcSEcCtD
Pseudoephedrine—Headache—Paclitaxel—kidney cancer	0.000135	0.00148	CcSEcCtD
Pseudoephedrine—Muscle spasms—Doxorubicin—kidney cancer	0.000134	0.00148	CcSEcCtD
Pseudoephedrine—ADRA1A—renal system—kidney cancer	0.000133	0.0425	CbGeAlD
Pseudoephedrine—MAOA—renal system—kidney cancer	0.000132	0.0421	CbGeAlD
Pseudoephedrine—SLC6A2—gonad—kidney cancer	0.000129	0.041	CbGeAlD
Pseudoephedrine—Agitation—Doxorubicin—kidney cancer	0.000128	0.00141	CcSEcCtD
Pseudoephedrine—Nausea—Paclitaxel—kidney cancer	0.000128	0.00141	CcSEcCtD
Pseudoephedrine—MAOA—kidney—kidney cancer	0.000128	0.0407	CbGeAlD
Pseudoephedrine—Asthenia—Capecitabine—kidney cancer	0.000127	0.00139	CcSEcCtD
Pseudoephedrine—Vertigo—Doxorubicin—kidney cancer	0.000125	0.00138	CcSEcCtD
Pseudoephedrine—MAOA—cortex of kidney—kidney cancer	0.000124	0.0397	CbGeAlD
Pseudoephedrine—Palpitations—Doxorubicin—kidney cancer	0.000123	0.00136	CcSEcCtD
Pseudoephedrine—Hypertension—Doxorubicin—kidney cancer	0.000121	0.00132	CcSEcCtD
Pseudoephedrine—Chest pain—Doxorubicin—kidney cancer	0.000119	0.00131	CcSEcCtD
Pseudoephedrine—Selegiline—ABCB1—kidney cancer	0.000119	0.0274	CrCbGaD
Pseudoephedrine—Anxiety—Doxorubicin—kidney cancer	0.000119	0.0013	CcSEcCtD
Pseudoephedrine—MAOA—cardiac atrium—kidney cancer	0.000118	0.0377	CbGeAlD
Pseudoephedrine—Dizziness—Capecitabine—kidney cancer	0.000117	0.00128	CcSEcCtD
Pseudoephedrine—Confusional state—Doxorubicin—kidney cancer	0.000115	0.00126	CcSEcCtD
Pseudoephedrine—Vomiting—Capecitabine—kidney cancer	0.000112	0.00124	CcSEcCtD
Pseudoephedrine—Rash—Capecitabine—kidney cancer	0.000112	0.00122	CcSEcCtD
Pseudoephedrine—Dermatitis—Capecitabine—kidney cancer	0.000111	0.00122	CcSEcCtD
Pseudoephedrine—Tachycardia—Doxorubicin—kidney cancer	0.000111	0.00122	CcSEcCtD
Pseudoephedrine—Headache—Capecitabine—kidney cancer	0.000111	0.00122	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Doxorubicin—kidney cancer	0.00011	0.00121	CcSEcCtD
Pseudoephedrine—Anorexia—Doxorubicin—kidney cancer	0.000109	0.00119	CcSEcCtD
Pseudoephedrine—Nausea—Capecitabine—kidney cancer	0.000105	0.00115	CcSEcCtD
Pseudoephedrine—Insomnia—Doxorubicin—kidney cancer	0.000103	0.00113	CcSEcCtD
Pseudoephedrine—Dyspnoea—Doxorubicin—kidney cancer	0.000102	0.00112	CcSEcCtD
Pseudoephedrine—Dyspepsia—Doxorubicin—kidney cancer	0.0001	0.0011	CcSEcCtD
Pseudoephedrine—Decreased appetite—Doxorubicin—kidney cancer	9.91e-05	0.00109	CcSEcCtD
Pseudoephedrine—Pain—Doxorubicin—kidney cancer	9.75e-05	0.00107	CcSEcCtD
Pseudoephedrine—ADRA2A—cortex of kidney—kidney cancer	9.55e-05	0.0304	CbGeAlD
Pseudoephedrine—Feeling abnormal—Doxorubicin—kidney cancer	9.39e-05	0.00103	CcSEcCtD
Pseudoephedrine—ADRA2A—gonad—kidney cancer	9.1e-05	0.029	CbGeAlD
Pseudoephedrine—ADRA2A—cardiac atrium—kidney cancer	9.08e-05	0.029	CbGeAlD
Pseudoephedrine—Body temperature increased—Doxorubicin—kidney cancer	9.01e-05	0.00099	CcSEcCtD
Pseudoephedrine—Asthenia—Doxorubicin—kidney cancer	8.18e-05	0.000898	CcSEcCtD
Pseudoephedrine—CYP2D6—renal system—kidney cancer	7.86e-05	0.025	CbGeAlD
Pseudoephedrine—CYP2D6—kidney—kidney cancer	7.6e-05	0.0242	CbGeAlD
Pseudoephedrine—Dizziness—Doxorubicin—kidney cancer	7.54e-05	0.000828	CcSEcCtD
Pseudoephedrine—Vomiting—Doxorubicin—kidney cancer	7.25e-05	0.000796	CcSEcCtD
Pseudoephedrine—Rash—Doxorubicin—kidney cancer	7.19e-05	0.00079	CcSEcCtD
Pseudoephedrine—Dermatitis—Doxorubicin—kidney cancer	7.18e-05	0.000789	CcSEcCtD
Pseudoephedrine—Headache—Doxorubicin—kidney cancer	7.14e-05	0.000784	CcSEcCtD
Pseudoephedrine—Nausea—Doxorubicin—kidney cancer	6.77e-05	0.000744	CcSEcCtD
Pseudoephedrine—CYP2D6—Metabolism—PGK1—kidney cancer	1.06e-05	6.3e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—SLC5A3—kidney cancer	1.06e-05	6.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—GRB7—kidney cancer	1.05e-05	6.29e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MAPK3—kidney cancer	1.05e-05	6.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	1.05e-05	6.26e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—LDHB—kidney cancer	1.04e-05	6.18e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—GSTP1—kidney cancer	1.03e-05	6.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PSMD7—kidney cancer	1.02e-05	6.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ANXA1—kidney cancer	1.02e-05	6.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TSC1—kidney cancer	1.02e-05	6.06e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MAPK1—kidney cancer	1e-05	5.98e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—KRAS—kidney cancer	1e-05	5.97e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—VEGFA—kidney cancer	9.96e-06	5.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—GSTT1—kidney cancer	9.93e-06	5.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ACHE—kidney cancer	9.93e-06	5.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PSMD7—kidney cancer	9.93e-06	5.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TSC1—kidney cancer	9.93e-06	5.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ANXA1—kidney cancer	9.93e-06	5.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FLT1—kidney cancer	9.83e-06	5.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ITPR2—kidney cancer	9.8e-06	5.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—GRB7—kidney cancer	9.8e-06	5.85e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—ABCB1—kidney cancer	9.76e-06	5.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FLT1—kidney cancer	9.62e-06	5.74e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—KRAS—kidney cancer	9.47e-06	5.65e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—GSTM1—kidney cancer	9.47e-06	5.65e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MAPK3—kidney cancer	9.42e-06	5.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—SCARB1—kidney cancer	9.4e-06	5.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTGS1—kidney cancer	9.31e-06	5.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—POMC—kidney cancer	9.27e-06	5.53e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—PIK3CA—kidney cancer	9.2e-06	5.49e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MYC—kidney cancer	9.16e-06	5.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PSMD7—kidney cancer	9.13e-06	5.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—JUNB—kidney cancer	9.12e-06	5.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PAK1—kidney cancer	9.12e-06	5.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ITPR2—kidney cancer	9.11e-06	5.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—RAF1—kidney cancer	9.1e-06	5.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—POMC—kidney cancer	9.07e-06	5.41e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CA9—kidney cancer	8.98e-06	5.36e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—CYP1A1—kidney cancer	8.98e-06	5.36e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MAPK1—kidney cancer	8.97e-06	5.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—JUNB—kidney cancer	8.92e-06	5.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PAK1—kidney cancer	8.92e-06	5.32e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—TP53—kidney cancer	8.9e-06	5.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CTNNA1—kidney cancer	8.89e-06	5.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EIF4EBP1—kidney cancer	8.84e-06	5.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HSPB1—kidney cancer	8.84e-06	5.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—BCHE—kidney cancer	8.65e-06	5.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—SLC5A5—kidney cancer	8.55e-06	5.1e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—KRAS—kidney cancer	8.47e-06	5.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—POMC—kidney cancer	8.42e-06	5.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CTNNA1—kidney cancer	8.26e-06	4.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—SLC2A1—kidney cancer	8.26e-06	4.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—POMC—kidney cancer	8.24e-06	4.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PSMD7—kidney cancer	8.22e-06	4.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TSC1—kidney cancer	8.22e-06	4.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ANXA1—kidney cancer	8.22e-06	4.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EIF4EBP1—kidney cancer	8.21e-06	4.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HSPB1—kidney cancer	8.21e-06	4.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—IL2—kidney cancer	8.16e-06	4.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FLT1—kidney cancer	7.96e-06	4.75e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—PIK3CA—kidney cancer	7.78e-06	4.64e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CRABP1—kidney cancer	7.64e-06	4.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PSMD7—kidney cancer	7.63e-06	4.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ANXA1—kidney cancer	7.63e-06	4.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TSC1—kidney cancer	7.63e-06	4.55e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TP53—kidney cancer	7.53e-06	4.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—POMC—kidney cancer	7.5e-06	4.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IGF2—kidney cancer	7.45e-06	4.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN2B—kidney cancer	7.42e-06	4.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FLT1—kidney cancer	7.39e-06	4.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—JUNB—kidney cancer	7.38e-06	4.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PAK1—kidney cancer	7.38e-06	4.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IGF2—kidney cancer	7.29e-06	4.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN2B—kidney cancer	7.26e-06	4.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IGF1R—kidney cancer	7.21e-06	4.3e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ITPR2—kidney cancer	7.1e-06	4.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IGF1R—kidney cancer	7.05e-06	4.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—POMC—kidney cancer	6.97e-06	4.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—RAF1—kidney cancer	6.94e-06	4.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—VEGFA—kidney cancer	6.93e-06	4.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—GSTP1—kidney cancer	6.89e-06	4.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—IL2—kidney cancer	6.86e-06	4.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—JUNB—kidney cancer	6.85e-06	4.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PAK1—kidney cancer	6.85e-06	4.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—POMC—kidney cancer	6.81e-06	4.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—RAF1—kidney cancer	6.79e-06	4.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—IL2—kidney cancer	6.71e-06	4e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—POMC—kidney cancer	6.69e-06	3.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—MAPK3—kidney cancer	6.56e-06	3.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ABCB1—kidney cancer	6.52e-06	3.89e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ACHE—kidney cancer	6.47e-06	3.86e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTT1—kidney cancer	6.47e-06	3.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—POMC—kidney cancer	6.33e-06	3.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—GSTM1—kidney cancer	6.33e-06	3.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—MAPK1—kidney cancer	6.24e-06	3.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL2—kidney cancer	6.23e-06	3.71e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—SCARB1—kidney cancer	6.13e-06	3.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL2—kidney cancer	6.09e-06	3.63e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTGS1—kidney cancer	6.07e-06	3.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IGF2—kidney cancer	6.03e-06	3.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN2B—kidney cancer	6e-06	3.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CYP1A1—kidney cancer	6e-06	3.58e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PSMD7—kidney cancer	5.95e-06	3.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HIF1A—kidney cancer	5.93e-06	3.54e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TSC2—kidney cancer	5.92e-06	3.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—KRAS—kidney cancer	5.89e-06	3.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	5.83e-06	3.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HIF1A—kidney cancer	5.8e-06	3.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TSC2—kidney cancer	5.79e-06	3.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KDR—kidney cancer	5.67e-06	3.38e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—BCHE—kidney cancer	5.64e-06	3.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	5.62e-06	3.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IGF2—kidney cancer	5.6e-06	3.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	5.58e-06	3.33e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.57e-06	3.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KDR—kidney cancer	5.55e-06	3.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	5.55e-06	3.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	5.42e-06	3.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—PIK3CA—kidney cancer	5.41e-06	3.23e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—SLC2A1—kidney cancer	5.38e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTGS2—kidney cancer	5.34e-06	3.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TP53—kidney cancer	5.24e-06	3.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KIT—kidney cancer	5.23e-06	3.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APC—kidney cancer	5.23e-06	3.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	5.22e-06	3.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	5.15e-06	3.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KIT—kidney cancer	5.11e-06	3.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APC—kidney cancer	5.11e-06	3.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL2—kidney cancer	5.04e-06	3e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	5e-06	2.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—POMC—kidney cancer	4.97e-06	2.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—BRAF—kidney cancer	4.91e-06	2.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	4.9e-06	2.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—POMC—kidney cancer	4.87e-06	2.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—BRAF—kidney cancer	4.81e-06	2.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	4.8e-06	2.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TSC2—kidney cancer	4.79e-06	2.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	4.76e-06	2.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL2—kidney cancer	4.68e-06	2.79e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	4.66e-06	2.78e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTEN—kidney cancer	4.66e-06	2.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KDR—kidney cancer	4.59e-06	2.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	4.55e-06	2.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—KRAS—kidney cancer	4.5e-06	2.68e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTP1—kidney cancer	4.49e-06	2.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—POMC—kidney cancer	4.47e-06	2.67e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	4.46e-06	2.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	4.45e-06	2.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TSC2—kidney cancer	4.45e-06	2.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—KRAS—kidney cancer	4.4e-06	2.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KDR—kidney cancer	4.26e-06	2.54e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ABCB1—kidney cancer	4.25e-06	2.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KIT—kidney cancer	4.23e-06	2.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APC—kidney cancer	4.23e-06	2.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	4.13e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTM1—kidney cancer	4.12e-06	2.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—RAF1—kidney cancer	4.1e-06	2.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—RELA—kidney cancer	4.08e-06	2.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ERBB2—kidney cancer	4.06e-06	2.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	4.05e-06	2.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	4.04e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—POMC—kidney cancer	4.02e-06	2.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—RAF1—kidney cancer	4.01e-06	2.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MTOR—kidney cancer	4e-06	2.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—RELA—kidney cancer	3.99e-06	2.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—BRAF—kidney cancer	3.97e-06	2.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ERBB2—kidney cancer	3.97e-06	2.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KIT—kidney cancer	3.93e-06	2.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APC—kidney cancer	3.93e-06	2.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MTOR—kidney cancer	3.92e-06	2.34e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.91e-06	2.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	3.85e-06	2.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	3.76e-06	2.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	3.76e-06	2.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—POMC—kidney cancer	3.74e-06	2.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—BRAF—kidney cancer	3.69e-06	2.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.68e-06	2.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL2—kidney cancer	3.68e-06	2.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	3.68e-06	2.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	3.64e-06	2.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL2—kidney cancer	3.6e-06	2.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCND1—kidney cancer	3.58e-06	2.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	3.58e-06	2.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—JUN—kidney cancer	3.58e-06	2.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTGS2—kidney cancer	3.57e-06	2.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	3.55e-06	2.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCND1—kidney cancer	3.51e-06	2.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—JUN—kidney cancer	3.5e-06	2.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	3.47e-06	2.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTEN—kidney cancer	3.46e-06	2.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	3.42e-06	2.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTEN—kidney cancer	3.38e-06	2.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	3.38e-06	2.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	3.34e-06	1.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	3.32e-06	1.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RELA—kidney cancer	3.3e-06	1.97e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PIK3CA—kidney cancer	3.28e-06	1.96e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	3.28e-06	1.96e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	3.24e-06	1.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—VEGFA—kidney cancer	3.13e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTEN—kidney cancer	3.11e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	3.11e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	3.08e-06	1.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RELA—kidney cancer	3.07e-06	1.83e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—VEGFA—kidney cancer	3.06e-06	1.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	3.05e-06	1.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	3.04e-06	1.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	3.01e-06	1.8e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2—kidney cancer	2.98e-06	1.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK3—kidney cancer	2.96e-06	1.76e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—POMC—kidney cancer	2.91e-06	1.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	2.9e-06	1.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—JUN—kidney cancer	2.89e-06	1.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK3—kidney cancer	2.89e-06	1.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MYC—kidney cancer	2.88e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	2.87e-06	1.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	2.83e-06	1.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK1—kidney cancer	2.81e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MYC—kidney cancer	2.81e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	2.8e-06	1.67e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2—kidney cancer	2.76e-06	1.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK1—kidney cancer	2.75e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	2.7e-06	1.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—JUN—kidney cancer	2.69e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	2.67e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KRAS—kidney cancer	2.66e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	2.6e-06	1.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KRAS—kidney cancer	2.6e-06	1.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	2.53e-06	1.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	2.44e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.39e-06	1.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	2.39e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TP53—kidney cancer	2.36e-06	1.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	2.35e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.33e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTGS2—kidney cancer	2.32e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TP53—kidney cancer	2.31e-06	1.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.28e-06	1.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	2.22e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CA—kidney cancer	2.19e-06	1.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MYC—kidney cancer	2.16e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	2.15e-06	1.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	2.11e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTEN—kidney cancer	2.03e-06	1.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	2e-06	1.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	1.98e-06	1.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TP53—kidney cancer	1.91e-06	1.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.84e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.78e-06	1.06e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.43e-06	8.53e-06	CbGpPWpGaD
